Categories AlphaGraphs, Earnings, LATEST, Technology
Trxade Health (MEDS) reports 6% growth in Q1 revenue; loss widens
Pharmaceutical services company Trxade Health Inc (NASDAQ: MEDS) Monday reported a widder net loss for the first quarter of 2022 despite a 6% increase in revenues. The top-line also beat analysts’ estimates.
First-quarter revenues increased 6% year-over-year to $3.2 million and came in above analysts’ estimates. The company added 339 registered members during the three-month period.
Trxade reported a net loss of $1 million or $0.12 per share for the first quarter, compared to a loss of $0.7 million or $0.08 per share in the year-ago quarter. The bottom line missed analysts’ estimates.
Check this space to read management/analysts’ comments on Trxade’s Q1 2022 results
Shares of Trxade closed Monday’s trading lower. The stock has lost about 41% so far this year.
Prior Performance
Most Popular
Trxade (MEDS) is increasing the breadth of product offerings: CEO Suren Ajjarapu
Trxade Health Inc. (NASDAQ: MEDS) is an online pharmaceutical marketplace that provides a platform for independent pharmacies to operate more effectively. The company’s digital platform helps optimize drug procurement and
AMAT Stock: Is now the right time to invest in Applied Materials?
It is estimated that the size of the global chip manufacturing equipment market would nearly double from the current levels to about $142 billion in the next eight years. Applied
Here’s a look at Take-Two Interactive Software’s (TTWO) expectations for the coming year
Shares of Take-Two Interactive Software (NASDAQ: TTWO) were down over 2% on Friday. The stock has dropped 32% year-to-date and 35% over the past 12 months. Earlier this week, the
